Pound P, Ram R, Archibald K
JRSM Open. 2025; 16(2):20542704251317916.
PMID: 40007990
PMC: 11848878.
DOI: 10.1177/20542704251317916.
Brucher B
J Healthc Leadersh. 2025; 17:23-43.
PMID: 40007855
PMC: 11853952.
DOI: 10.2147/JHL.S506767.
Pastorino A, Sobrero A, Bruzzi P
BMJ Oncol. 2025; 2(1):e000179.
PMID: 39886497
PMC: 11234984.
DOI: 10.1136/bmjonc-2023-000179.
Gupta M, Akhtar O, Bahl B, Mier-Hicks A, Attwood K, Catalfamo K
BMJ Oncol. 2025; 3(1):e000369.
PMID: 39886148
PMC: 11256025.
DOI: 10.1136/bmjonc-2024-000369.
Yoo S, Fitzgerald C, Cho B, Fitzgerald B, Han C, Koh E
Nat Med. 2025; .
PMID: 39762425
DOI: 10.1038/s41591-024-03398-5.
Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022.
Zhang X, Peck C, Wang Y, Szucs T, Sun W, Bai X
BMC Med. 2024; 22(1):587.
PMID: 39695642
PMC: 11657587.
DOI: 10.1186/s12916-024-03800-6.
Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China.
Luo X, Xu Y, Du X, Lv X, Chen S, Yang Y
Lancet Reg Health West Pac. 2024; 52:101238.
PMID: 39582601
PMC: 11582467.
DOI: 10.1016/j.lanwpc.2024.101238.
Modeling Overall Survival in Patients With Pancreatic Cancer From a Pooled Analysis of Phase II Trials.
Kabir E, Azam F, Khan T, Yasmin H, Chowdhury N, Ahmed S
Cancer Med. 2024; 13(19):e70289.
PMID: 39387320
PMC: 11465028.
DOI: 10.1002/cam4.70289.
Estimating the replicability of highly cited clinical research (2004-2018).
da Costa G, Neves K, Amaral O
PLoS One. 2024; 19(8):e0307145.
PMID: 39110675
PMC: 11305584.
DOI: 10.1371/journal.pone.0307145.
Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost.
Chitoran E, Rotaru V, Ionescu S, Gelal A, Capsa C, Bohiltea R
Cancers (Basel). 2024; 16(14).
PMID: 39061228
PMC: 11274419.
DOI: 10.3390/cancers16142590.
An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
Elbaz J, Haslam A, Prasad V
Cancer Med. 2024; 13(8):e7190.
PMID: 38659418
PMC: 11043668.
DOI: 10.1002/cam4.7190.
Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
Yoon N, Na Y, Lee J, Song I, Lee E, Park M
J Cancer Res Clin Oncol. 2024; 150(3):113.
PMID: 38436796
PMC: 10912263.
DOI: 10.1007/s00432-023-05587-0.
Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis.
Gharzai L, Morris E, Suresh K, Nguyen-Tan P, Rosenthal D, Gillison M
Lancet Oncol. 2024; 25(3):366-375.
PMID: 38423050
PMC: 10962533.
DOI: 10.1016/S1470-2045(24)00016-0.
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.
Brinkhuis F, Goettsch W, Mantel-Teeuwisse A, Bloem L
BMJ. 2024; 384:e077391.
PMID: 38418086
PMC: 10899806.
DOI: 10.1136/bmj-2023-077391.
Are We Losing the Final Fight against Cancer?.
Storme G
Cancers (Basel). 2024; 16(2).
PMID: 38275862
PMC: 10814389.
DOI: 10.3390/cancers16020421.
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
Cliff E, Rome R, Kesselheim A, Rome B
JAMA Netw Open. 2023; 6(11):e2343285.
PMID: 37962889
PMC: 10646727.
DOI: 10.1001/jamanetworkopen.2023.43285.
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed.
Walia A, Tuia J, Prasad V
Nat Rev Clin Oncol. 2023; 20(12):885-895.
PMID: 37828154
DOI: 10.1038/s41571-023-00823-5.
Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis.
Nguyen T, Nhu N, Chen C, Lin C
Cancer Med. 2023; 12(18):18767-18785.
PMID: 37667978
PMC: 10557829.
DOI: 10.1002/cam4.6497.
Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?.
Chauca Strand G, Johansson N, Jakobsson N, Bonander C, Svensson M
Clin Drug Investig. 2023; 43(8):621-633.
PMID: 37505421
PMC: 10480259.
DOI: 10.1007/s40261-023-01285-4.
External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations.
Silva P, Janjan N, Ramos K, Udeani G, Zhong L, Ory M
Front Med (Lausanne). 2023; 10:1198088.
PMID: 37484840
PMC: 10359981.
DOI: 10.3389/fmed.2023.1198088.
